RepliCel Life Sciences has signed agreements with two European firms—Austrian manufacturer AMI and Art of Technology (“AoT”), based in Zurich—to manufacture and test the company’s motorized RCI-02 dermal injector prototypes.
The RCI-02 injector was designed to improve the delivery of injectables in a controlled and precise manner in order to minimize the risks and uncertainties of injection outcomes. The device has programmable depth and volume; a built-in Peltier element for pre-injection anesthesia; and interchangeable needle head configurations that can be used to perform a variety of procedures, increase surface area coverage and speedup procedure times.
“The execution of these agreements covers what we believe to be the final stages needed to prepare RCI-02 for a market authorization application in the form of a CE mark in Europe,” said RepliCel president and CEO R. Lee Buckler. “With our first functional prototypes scheduled for this summer, we continue to work toward having this device ready for a CE mark application and in the hands of a licensing and commercial partner next year.”
